Although finerenone, SGLT2i and GLP-1 RA offered cardiovascular or renal benefits to patients with T2DM and CKD, currently, there was no comparable study focusing on their effects on cardiovascular and renal outcomes. Here, GCG is linked to type 2 diabetes mellitus.